Nova Mentis Life Science Corp. (formerly Liberty Leaf Holdings Ltd.) is a Canadian-based, public company whose focus is to build and support a diversified portfolio of health and wellness businesses. Key holdings include its wholly-owned subsidiary, Nova Mentis Biotech Corp., a R&D driven company focused on exploring the anti-inflammatory effects of psilocybin in underexplored metabolic indications such as obesity and diabetes – Just Kush Enterprises, an Okanagan BC based, Health Canada Standard Licensed facility focused on the cultivation of premium, small batch Kush dominant cultivars.
Stock Performance
Nova Mentis Life Science Corp News 21 articles
- Nova Mentis Assigns Intellectual Property
- Nova Mentis’ Psilocybin Preclinical Study Published in International Science Journal
- Wellbeing Subsidiary KGK Science Enters into Research Contract With Nova Mentis for Phase II A Clinical Trial
- Nova Mentis Enters into Research Contract with KGK Science for Phase II A Clinical Trial
- Nova Mentis Psilocybin Microdose Capsule Formulation to be Submitted in Health Canada Phase 2A Clinical Trial Application
- Nova Mentis Completes Production of Psilocybin Microdose Capsules
- Nova Mentis Files Patent on Diagnosing, Monitoring and Treating Neurological Diseases with Psychoactive Tryptamine Derivatives
- Nova Mentis and University of Central Florida to Develop Saliva Serotonin Assay
- Nova Mentis Receives Controlled Substances Export Approval From DEA For Proprietary Psilocybin Drug
- Nova Mentis Psilocybin Manufacturer Receives Approved Health Canada Importation Permit
- Nova Mentis to Produce Psilocybin Capsules for Phase 2A Clinical Study
- Nova Mentis Study Confirms Oral Microdose Psilocybin Treatment of Autism
- U.S. FDA Approves Nova Mentis Orphan Drug Application
- Mycrodose Therapeutics and Nova Mentis Announce LOI to Co-Develop Advanced Drug Delivery System
- Nova Mentis Life Science Applies to US FDA for Psilocybin Orphan Drug Designation Fragile X Syndrome Treatment
- Nova Mentis Files U.S. Patent Application for Psilocybin-Based Therapeutics
- Nova Mentis Appoints Dr. Stephen Glazer as Director and Chief Science Officer
- Nova Mentis Organizes Autism Data Bank in North America
- Nova Mentis Upgrades U.S. Listing to the OTCQB Venture Market
- Nova Mentis Life Science Acquisition Target, Pilz Bioscience Corp, Signs Psilocybin Manufacturing Agreement
- Nova Mentis Life Science Signs Agreement to Acquire 100% of Psychedelic-Focused Autism Research Company Pilz BioScience Corp.